PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

The new investment will support both organic and inorganic expansion, including growth in sterile fill-finish injectables, ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

(Reuters) -Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter. The ...

(Reuters) -Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter.

PCI Pharma Services has secured a new round of strategic investment, with Bain Capital joining existing lead investor Kohlberg and reinvestment partner Mubadala Investment Company to support ...